Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.53 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ECE1 | P42892 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10292032 | 1.00 | ATM (0.53) | ATMGBA2POLBLMNASMN1; SMN2 | |
| SCHEMBL10084437 | 1.00 | ATM (0.53) | ATMGBA2POLBLMNASMN1; SMN2 | |
| SCHEMBL10084439 | 1.00 | ATM (0.53) | ATMGBA2POLBLMNASMN1; SMN2 | |
| SCHEMBL31728231 | 1.00 | ATM (0.53) | ATMGBA2POLBLMNASMN1; SMN2 | |
| SCHEMBL20558080 | 1.00 | ATM (0.53) | ATMGBA2POLBLMNASMN1; SMN2 | |
| SCHEMBL1585134 | 0.88 | GBA2 (0.46) | ATMGBA2POLBLMNASMN1; SMN2 | |
| SCHEMBL10085243 | 0.87 | GBA2 (0.42) | ATMGBA2POLBLMNASMN1; SMN2 | |
| SCHEMBL10084421 | 0.87 | GBA2 (0.42) | ATMGBA2POLBLMNASMN1; SMN2 | |
| SCHEMBL30070929 | 0.86 | ATM (0.61) | ATMPOLBALDH1A1RAB9AMME | |
| SCHEMBL18065023 | 0.86 | RAB9A (0.42) | ATMGBA2POLBLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024034123-A1 | PHARMACEUTICAL COMPOSITION CONTAINING HETEROCYCLIC COMPOUND | アステラス製薬株式会社 | 2024-02-15 | — | — | WO | disclosed |
| WO-2024034657-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HETEROCYCLIC COMPOUND | アステラス製薬株式会社 | 2024-02-15 | — | — | WO | disclosed |
| US-20230373978-A1 | HETEROARYL-SUBSTITUTED IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-11-23 | — | — | US | disclosed |
| WO-2023171781-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | アステラス製薬株式会社 | 2023-09-14 | — | — | WO | disclosed |
| WO-2010033466-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C PROTEASE | PHENOMIX CORPORATION (US) | 2010-03-25 | — | — | WO | disclosed |
| US-5629406-A | AMINO ACID DERIVATIVES | SANKYO COMPANY, LIMITED (JP) | 1997-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373978-A1 | HETEROARYL-SUBSTITUTED IMIDAZOLE DERIVATIVES | F3, ABL1, CFTR | ATM 2053/4885GBA2 1459/4885POLB 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.